Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
Overview
Optimal surgical therapy (debridement in chronic osteomyelitis; device exchange in patients with chronic prosthetic joint infection [PJI]) could be sometimes non-feasible, especially in the elderly population. Therefore, a medical therapy with oral prolonged suppressive antibiotic therapy (PSAT) seems to be an option to prevent recurrence and prosthesis loosening. Unfortunately, some patients are infected with resistant pathogens for which oral antibiotics are not suitable. Subcutaneous (SC) administration of injectable intravenous antibiotics as PSAT could be a convenient way to limit catheter-related complications and facilitate ambulatory care. However, there are few data concerning the development of resistance under subcutaneous prolonged treatment with betalactamine. The aim of this study is is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. Later analysis will be led on those samples to detect the acquisition of resistance or not.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: July 19, 2023
Interventions
- Other: BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE
- collection of saddles
Arms, Groups and Cohorts
- BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE
- The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
Clinical Trial Outcome Measures
Primary Measures
- BIOLOGICAL COLLECTION FROM SAMPLES FROM THE GUT MICROBIOTE
- Time Frame: 36 months
- The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
Participating in This Clinical Trial
Inclusion Criteria
- Patients having an ostéo-articular infection (on material or on native bone) and having an indication of antibiotic treatment suppressive subcutaneous by betalactamine and managed at the Croix-Rousse Hospital – Patients not opposed to participate to the study Exclusion Criteria:
- none
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 100 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hospices Civils de Lyon
- Provider of Information About this Clinical Study
- Principal Investigator: Eugénie MABRUT, Clinical Research Assistant – Hospices Civils de Lyon
- Overall Official(s)
- Tristan Ferry, Md,PhD, Principal Investigator, Hospices Civils de Lyon – Hopital de la Croix Rousse
- Overall Contact(s)
- Eugenie mabrut, 04 26 73 29 38, eugenie.mabrut@chu-lyon.fr
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.